RT Journal Article
SR Electronic
T1 Risk Factors for New Neurologic Diagnoses in Hospitalized Patients With COVID-19
JF Neurology: Clinical Practice
FD Lippincott Williams & Wilkins
SP e66
OP e74
DO 10.1212/CPJ.0000000000200006
VO 12
IS 4
A1 Kiran T. Thakur
A1 Victoria T. Chu
A1 Christine Hughes
A1 Carla Y. Kim
A1 Shannon Fleck-Derderian
A1 Catherine E. Barrett
A1 Elizabeth Matthews
A1 Alanna Balbi
A1 Amanda Bilski
A1 Mashina Chomba
A1 Ori Lieberman
A1 Samuel D. Jacobson
A1 Sachin Agarwal
A1 David Roh
A1 Soojin Park
A1 Vivian Ssonko
A1 Wendy G. Silver
A1 Wendy D. Vargas
A1 Andrew Geneslaw
A1 Michelle Bell
A1 Brandon Waters
A1 Agam Rao
A1 Jan Claassen
A1 Amelia Boehme
A1 Joshua Z. Willey
A1 Mitchell S.V. Elkind
A1 Magdalena E. Sobieszczyk
A1 Jason Zucker
A1 Andrea McCollum
A1 James Sejvar
YR 2022
UL http://cp.neurology.org/content/12/4/e66.abstract
AB Background and Objectives There have been numerous reports of neurologic manifestations identified in hospitalized patients infected with SARS-CoV-2, the virus that causes COVID-19. Here, we identify the spectrum of associated neurologic symptoms and diagnoses, define the time course of their development, and examine readmission rates and mortality risk posthospitalization in a multiethnic urban cohort.Methods We identify the occurrence of new neurologic diagnoses among patients with laboratory-confirmed SARS-CoV-2 infection in New York City. A retrospective cohort study was performed on 532 cases (hospitalized patients with new neurologic diagnoses within 6 weeks of positive SARS-CoV-2 laboratory results between March 1, 2020, and August 31, 2020). We compare demographic and clinical features of the 532 cases with 532 controls (hospitalized COVID-19 patients without neurologic diagnoses) in a case-control study with one-to-one matching and examine hospital-related data and outcomes of death and readmission up to 6 months after acute hospitalization in a secondary case-only analysis.Results Among the 532 cases, the most common new neurologic diagnoses included encephalopathy (478, 89.8%), stroke (66, 12.4%), and seizures (38, 7.1%). In the case-control study, cases were more likely than controls to be male (58.6% vs 52.8%, p = 0.05), had baseline neurologic comorbidities (36.3% vs 13.0%, p < 0.0001), and were to be treated in an intensive care unit (62.0% vs 9.6%, p < 0.0001). Of the 394 (74.1%) cases who survived acute hospitalization, more than half (220 of 394, 55.8%) were readmitted within 6 months, with a mortality rate of 23.2% during readmission.Discussion Hospitalized patients with SARS-CoV-2 and new neurologic diagnoses have significant morbidity and mortality postdischarge. Further research is needed to define the effect of neurologic diagnoses during acute hospitalization on longitudinal post-COVID-19–related symptoms including neurocognitive impairment.